Immune-Onc Therapeutics Inc. is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that reverse immune suppression in the tumor microenvironment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/06/23 | $131,000,000 | Series B |
Leukemia & Lymphoma Society Therapy Acceleration Program Proxima VC Triwise Capital  WuXi Biologics | undisclosed |
